



9th EUROPEAN
CONFERENCE on
INFECTIONS in
LEUKAEMIA



► **IN-PERSON CONFERENCE**
From September
15th to 17th 2022

Revised Guidelines
slide set
September 2022

UPDATE 2022

COVID19: Clinical symptoms and infection control and the prevention management of positive patient (and positive donor in case HCT)

Marie von Lilienfeld-Toal (Jena, Germany);

Francesco Marchesi (Rome, Italy);

Simone Cesaro (Verona, Italy);

Jan Styczynski (Bydgoszcz, Poland)



► **IN-PERSON CONFERENCE
2022**

Revised Guidelines slide set September 2022

COVID-19: clinical symptoms and course of the disease

Typical symptoms in HM patients

UPDATE 2022

- The most common symptoms of COVID-19 in HM patients are similar to the overall population
- With Omicron, cough is the most common symptom (70%), fever around 40% and sore throat around 60%
- Loss of taste/smell is less frequent with Omicron
- Other common symptoms are breathlessness (37-49.3%) and fatigue (20.3-50%)
- Immunosuppressed patients may present atypical symptoms such as diarrhea, vomiting, loss of appetite and confusion
- A severe clinical presentation occurs in about 15-52.4% of cases in HM patients, depending on vaccination status and VOC
- Critical cases range between 6.9-14% in the most relevant published studies
- The incidence of breakthrough SARS-CoV-2 infections is variable among the published studies, as a consequence of different study designs and circulating VOC. Overall, the estimated incidence of breakthrough SARS-CoV-2 in HM patients ranges between 0.3% and 8%

References. Passamonti, et al. Lancet Haematol 2020; Cattaneo, et al. Cancer 2020; Borah, et al. Blood Cell Molec Dis 2021; Glenthøj, et al. Eur J Haematol 2020; Wood, et al. Blood Adv 2020 Kurderer, et al. Lancet 2020; Lee, et al. Lancet Oncol 2020; Yigenogin, et al. J Med Virol 2021; Regalado-Artamendi, et al. Hemasphere 2021; García Suárez, et al. J Hematol Oncol 2020; Pinana, et al. Exp Hematol Oncol 2020; Sharma, et al. Lancet Haematol 2021; Giesen, et al. Eur J Cancer 2020; Giesen, et al. Eur J Cancer 2021; ElGohary, et al. Hematol Oncol Stem Cell Ther 2020 Ali, et al. Hematol Oncol Stem Cell Ther 2020; Coronavirus disease COVID-19: EBMT recommendations version 15 – February 17, 2021; Ljungman, et al. Leukemia 2021. Vihta medRxiv 2022; Schulze Front Virol 2022; Pagano Blood 2022; Mittelman M, et al. Blood 2022; Maneikis K, et al. Lancet Haematol 2021; Lee LYM, et al. Lancet Oncol 2022; Savini M, et al. Am J Hematol 2022].



► **IN-PERSON CONFERENCE
2022**

Revised Guidelines slide set September 2022

COVID-19: clinical symptoms and course of the disease

Update on «long-COVID» in HM patients

UPDATE 2022

- A comprehensive meta-analysis including 31 studies estimated a post-COVID-19 condition prevalence of 0.43% (95%CI: 0.39-0.46) in the overall population
- Data on cancer patients show that post COVID-19 sequaele affect up to 15% of patients with cancer and adversely influence survival and oncological outcomes and recovery
- Few specific data have been published focusing only on HM patients, showing similar clinical presentation to that observed in the overall population
- Older age, comorbidities, COVID-19 treatment, COVID-19 complications and/or hospitalisation occurrence during the acute phase are the main risk factors for long-COVID-19 in cancer patients
- Community-base cohort studies showed that vaccinated people were less likely than unvaccinated people affected by long-COVID. There are not published data about this issue in HM patients
- The incidence and severity of long-COVID in HM patients deserves further investigation

References. Chen et al. J Infect Dis 2022; Pinato et al. Lancet Oncol 2021; Chopra et al. Ann Int Med 2020; Huang et al. Lancet 2021; Cortellini et al. Eur J Cancer 2022; Barbui et al. Blood Cancer J 2021; Ayoubkhani et al. BMJ 2022; Antonelli et al. Lancet Infect Dis 2022; Al-Aly et al. Nat Med 2022



► **IN-PERSON CONFERENCE
2022**

Revised Guidelines slide set September 2022

Multisystem inflammatory syndrome in children (MIS-C)

Definitions:

1. World Health Organization (WHO) criteria (MIS-C)
2. Centers for Disease Control and Prevention (CDC) criteria (MIS-C)

MIS-C described and defined but low incidence in pediatric HM

Multisystem inflammatory syndrome in adults (MIS-A)

MIS in adults (MIS-A) is a rare clinical entity, its long-term sequelae are largely unknown.

MIS-A, reported in 2021-2022, but rare in general population and no description in HM patients yet

(Patel et al., 2021; Kunal et al., 2022)



Deferral of therapy

COVID19 symptomatic HCT and HM patients

- For patients planned for allogeneic or autologous HCT or CAR-T and diagnosed with COVID-19, we recommend deferral of conditioning therapy due to the high propensity for LRTID and high mortality. **Allt**
- In HM patients with COVID-19, we suggest deferral of chemotherapy after assessment of clinical risk/benefit ratio on the patient individual basis. **Blllu**

Asymptomatic SARS-CoV-2 infection in HCT and HM patients

- In HM patients with asymptomatic SARS-CoV-2 infection and no previous COVID19 disease, we suggest the deferral of HCT, CAR-T therapy, therapy with MoAbs, and other non-cellular therapies after assessment of clinical risk/benefit ratio on the patient individual basis. **Blllu**

Asymptomatic SARS-CoV-2 infection, but persistently shedding the virus

- In case of patient who became asymptomatic after a previous COVID19 disease but he/she is persistently shedding the virus, we suggest the deferral of HCT, CAR-T therapy, therapy with MoAbs, and other non-cellular therapies after assessment of clinical risk/benefit ratio on the patient individual basis. **Blllu**



DONOR DEFERRALS and cryopreservation

UPDATE 2022

Donor diagnosed with COVID-19

- 7 days after clinical recovery. **BIII**
- For asymptomatic infections, 7 days after the most recent positive test result.

Contact with a person diagnosed with COVID-19

- For at least 14 days after last contact. **BIII**

Practice good hygiene and socially isolated

- Within 14 days of donation. **BIII**

Unnecessary travel should be avoided

- If the patient's need for transplant is urgent, the donor is completely well, a test is negative for SARS-CoV-2 and there are no suitable alternative donors, earlier collection may be considered subject to careful risk assessment, i.e. 7 days post-contact if an asymptomatic donor tests negative.
- Cryopreservation of the graft is an option for PBSC from RD and URD. **BIII**

Cryopreservation of allogeneic HPC grafts is a reasonable option that might be implemented after benefit-risk assessment.

DONOR TESTING: in the absence of symptoms, testing the donor for SARS-CoV-2 at the point of collection, or testing the donation itself, is not mandatory but local or country policy can be applied.



► **IN-PERSON CONFERENCE
2022**

Revised Guidelines slide set September 2022

WMDA guidelines

Comments on revised guidelines

You can send your comments about the Clinical symptoms group revised guidelines before Octobre 31st to the group leader:

- Simone Cesaro: simone.cesaro@aovr.veneto.it



► IN-PERSON CONFERENCE
2022